Pain is a major problem for patients with cancer. Meta-analyses report that most patients with advanced or metastatic cancer experience pain ([Hearn and Higginson, 2003](#bib20){ref-type="other"}; [van den Beuken-van Everdingen *et al*, 2007](#bib29){ref-type="other"}). Although several guidelines for cancer pain management have been published since 1986 ([Jacox *et al*, 1994](#bib21){ref-type="other"}; [WHO, 1996](#bib33){ref-type="other"}; [Hanks *et al*, 2001](#bib18){ref-type="other"}; [Cohen *et al*, 2003](#bib10){ref-type="other"}; [SIGN, 2008](#bib28){ref-type="other"}), undertreatment is well documented and can reach 82% of patients in some settings ([Di Maio *et al*, 2004](#bib14){ref-type="other"}). A recent systematic review based on 26 papers published from 1994 to 2007 suggests that nearly one of two patients with cancer pain is undertreated with a wide variability across studies and settings ([Deandrea *et al*, 2008](#bib13){ref-type="other"}). Undertreatment is usually attributed to inappropriate use of opioids on account of several reasons related to the healthcare provider, patient, family, institution and society ([Maltoni, 2008](#bib23){ref-type="other"}), where fear of opioids may be the most important determinant from the patient\'s point of view ([Reid *et al*, 2008](#bib26){ref-type="other"}).

In Italy, opioid consumption rates are yet among the lowest in Europe ([De Conno *et al*, 2005](#bib11){ref-type="other"}), although last year there was a small increase, mainly because of a change in the type of drugs prescribed than to an increase in the number of patients treated ([Osservatorio Nazionale sull\'impiego dei farmaci, 2007](#bib25){ref-type="other"}). As recently pointed out, poor information and communication may be a further barrier to a correct access to analgesic and palliative care and to hospice admission ([Harrington and Smith, 2008](#bib19){ref-type="other"}).

To improve the quality of cancer pain management, the Mario Negri Institute implemented a project on 2004 in Italy ([Apolone *et al*, 2004](#bib3){ref-type="other"}, [2006a](#bib1){ref-type="other"}), and an Outcome Research study was launched in 2006. The objectives were (a) to describe a large cohort of cancer patients in terms of pain characteristics, patterns of care and patient-reported outcomes; (b) to assess the quality of analgesic treatments in terms of congruence between the reported level of pain intensity of patients and the potency of the prescribed analgesic drug; (c) to compare the effects of various analgesic options, using appropriate statistical methods, such as the propensity score. This study reports on details about the design of the study, the type of patients recruited, the analgesic drugs prescribed and the quality of analgesic care administered.

Patients and methods
====================

Study design and patients
-------------------------

Background and methods are described elsewhere ([Apolone *et al*, 2006a](#bib1){ref-type="other"}, [2006b](#bib2){ref-type="other"}, [2008](#bib4){ref-type="other"}). Briefly, the data reported here were collected as part of a multicentre, open-label, prospective, non-randomised study. Each centre admitted up to 25 patients with diagnostic evidence of advanced/metastatic solid tumour; persistent pain, of any degree of intensity related to cancer, requiring or already on analgesic treatment; age ⩾18 years; life expectancy more than 1 month; and able to read, understand and provide informed consent to participate.

After enrolment/inclusion, the following screening assessments were carried out and recorded weekly for the first month, with a final visit at week 12 (at the end of the study): (a) medical history including cancer history, (b) physical examination, (c) record of medications and recent therapies, including analgesic consumption, (d) pain and symptom assessment, (f) patients\' and physicians\' satisfaction with pain treatment and (g) patient\'s self-reported quality of life.

Outcomes and endpoints
----------------------

Patients\' and physicians\' reports were collected using standardised forms at scheduled visits. Self-administered questionnaires were completed when the patient attended regular visits at the centre or during admission or at home depending on the setting of care. Investigators recorded information about patients and disease, pain medications and type and number of rescue doses in a case report form.

Pain characteristics (intensity, relief and so on) were the primary outcome measures. Other patient-reported outcomes were collected too, such as satisfaction with care, quality of life and symptoms. Pain was measured using five items from the Italian version of the Brief Pain Inventory ([Caraceni *et al*, 1996](#bib6){ref-type="other"}) assessing intensity of worst, present, least and average pain and pain relief with an 11-point numerical rating scale.

We used two methods to evaluate the analgesic undertreatment. First, we applied the pain management index (PMI), developed by [Cleeland *et al* (1994)](#bib8){ref-type="other"}. According to the World Health Organisation\'s (WHO) guidelines for the management of pain in cancer, treatment is considered adequate when there is congruence between the reported level of pain of the patient and the potency of the prescribed analgesic drug (its place on the WHO analgesic ladder; [WHO, 1996](#bib33){ref-type="other"}). The PMI compares the most potent analgesic prescribed for a patient with the reported level of the worst pain of that patient.

To construct the index, we determined which of four levels of analgesic drug therapy was the most potent one used: 0, no analgesic drug; 1, a non-opioid (e.g., a non-steroidal anti-inflammatory drug); 2, a weak opioid (e.g., codeine or tramadol); and 3, a strong opioid (e.g., morphine, fentanyl, buprenorphine, oxycodone and so on). We then determined the patient\'s level of pain from the Brief Pain Inventory (1--3, mild; 4--7, moderate; 8--10, severe). No pain was scored as 0; mild pain, 1; moderate pain, 2; and severe pain, 3. The PMI, computed by subtracting the pain level from the analgesic level, ranges from −3 (a patient with severe pain receiving no analgesic drugs) to +3 (a patient receiving morphine or an equivalent and reporting no pain). Negative scores are considered to indicate pain undertreatment, and scores of 0 or higher are considered a conservative indicator of acceptable treatment (see [Figure 1](#fig1){ref-type="fig"}).

As the PMI provides only a rough estimate of how pain is treated in a sample taking into account only some attributes of the pain characteristics ([Deandrea *et al*, 2008](#bib13){ref-type="other"}), we also assembled a list of clinical indicators to capture the appropriateness of the analgesic care delivered more directly. Operationally, we identified four specific clinical conditions where there was evidence that pain should be treated with a specific approach according to available guidelines: presence of episodes of breakthrough pain to be treated with a strong opioid as rescue/escape therapy, presence of neuropathic pain to be treated with a specific adjuvant drug, pain with intensity higher than 7 points, calling for a strong opioid as around-the-clock therapy, and presence of bone metastasis to be treated with bisphosphonates, ([Hanks *et al*, 2001](#bib18){ref-type="other"}; [Wong and Wiffen, 2002](#bib32){ref-type="other"}; [CEVEAS, 2004](#bib7){ref-type="other"}; [SIGN, 2008](#bib28){ref-type="other"}). Then, we estimated the proportion of patients in each group who did not receive the recommended therapy, as additional indicators of the quality of analgesic therapy. Frequencies were then associated with some variables, such as type of patient and recruiting centre.

Given the large number of centres, we used a web-based system to optimise the handling of all aspects of the clinical study, including data entry, quality assurance and validation. A general data entry engine for clinical trials developed by the Mario Negri Institute was used, which was compliant with current laws concerning ethical and regulatory issues ([Clivio *et al*, 2006](#bib9){ref-type="other"}). Before implementation, it was tested with a pilot feasibility study in 130 centres in 2005.

Statistical analysis
--------------------

On the basis of the literature and the results of the pilot study in 2005, we assumed that 100 centres during a 2-month inception period (recruitment) could see and evaluate up to 2500 eligible cases. We also assumed that at least half would already be receiving a WHO level III treatment and most of the others would eventually need a WHO level III analgesic during the longitudinal evaluation period.

There were no formal estimates of the proportion of cases who might be classified as undertreated at inclusion, although, on the basis of a systematic review of the literature pertaining to the PMI ([Deandrea *et al*, 2008](#bib13){ref-type="other"}), it was expected that up to 40% of patients might be receiving, at the time of study inclusion, an analgesic treatment not adequate to their intensity of pain. All patients enrolled in the study and eligible were included in the present analysis.

In the descriptive analysis, absolute frequency was used for categorical variables and central trend and dispersion measurements (mean, median and s.d.) for quantitative continuous variables. When comparing groups, *χ*^2^-tests for associations were used for categorical variables, such as whether or not patients experienced a given event. For continuous variables, such as mean differences in pain intensity, *t*-tests or one-way-analysis of variance, were used. For binary dependent variables, such as whether or not the patient had an analgesic undertreatment according to the PMI, estimates of association with potential independent variables were expressed in terms of odds ratios (ORs). After univariate analysis, a logistic model was fitted using maximum likelihood estimation to express the odds of each variable relative to the reference category, after adjustment for all other covariates. For example, the risk of being classified as undertreated for a patient with 70 years of age or more was compared to one younger than 51 years, given the same sex, type of cancer and analgesic adjuvant therapy. In addition, 95% confidence intervals of the ORs were computed.

Given the observational nature of the study, the relatively large sample size and the number of statistical tests, *P*-values must be considered with cautions as merely suggestive of a trend.

Ethical considerations
----------------------

The study complied with Italian requirements for observational studies. The protocol was approved by the local research ethics committees of participating centres. All patients gave written informed consent to participate in the study. The full study protocol was published in an open-access journal before the study started ([Apolone *et al*, 2006b](#bib2){ref-type="other"}).

Results
=======

As shown in [Figure 2](#fig2){ref-type="fig"}, 110 centres recruited 1801 valid cases that constitute the baseline cross-sectional sample, from February 2006 to March 2007. There were 1461 patients with complete data at 28 days and they form the longitudinal sample. This study focuses on the baseline sample.

As shown in [Table 1](#tbl1){ref-type="table"}, patients recruited were more frequently male, and had severe pain (mean worst pain at baseline 6.8). Half had bone metastasis, episodes of breakthrough pain and were still on active anticancer treatment. The most frequent primary cancers were lung, breast and colorectal cancers. Nearly two-thirds were recruited by oncologic centres, and the majority were not aware of their prognosis. Most had already been admitted at the centre when enrolled in the study. In all, 61% of patients were received a WHO-level III opioid, fentanyl and buprenorphine transdermal delivery systems being the most widely prescribed (in about 39% of cases); 47% received some kind of rescue/escape therapy, which was an anti-inflammatory drug in 53% of cases; oral morphine was the most widely prescribed strong opioid as recue therapy. A total of 60% also received some kind of adjuvant analgesic therapy.

We first assembled the PMI using all four items of the Brief Pain Inventory. [Table 2](#tbl2){ref-type="table"} shows, as expected, that different pain items generated different undertreatment estimates (8.9--25.3%). As recommended by [Cleeland *et al* (1994)](#bib8){ref-type="other"}, we used the worst pain item as main outcome. According to the literature suggesting wide variations on the basis of several variables related to patients, centres and settings ([Deandrea *et al*, 2008](#bib13){ref-type="other"}), we first conducted a bivariate analysis to identify the potential predictors of undertreatment, then a multivariable analysis to estimate the effect of each potential confounder on the association between predictors and occurrence of undertreatment. [Tables 3](#tbl3){ref-type="table"}, [4](#tbl4){ref-type="table"} and [5](#tbl5){ref-type="table"} report the results of both analyses.

When patients were classified according to the time of the follow-up or treatment before inclusion (new incident cases *vs* patients already in follow-up at the centre), there was a clear tendency: the proportion of undertreatment ranged from 44.7 to 20.2% with a consistent and statistically significant gradient (*P*\<0.0001). Among the other potential predictors tested with univariate analyses, the absence of bone metastasis and ongoing chemotherapy, being recruited in pain and palliative centres, having a colorectal cancer, and not receiving adjuvant analgesic therapy, were significantly associated with a higher probability of being classified as undertreated (OR=\>1.2 and *P*\<0.05). After multivariable logistic regression, only type of recruiting centre (*P*\<0.01), receiving adjuvant therapy or not (*P*\<0.001), and type of patient recruited (new or already on follow-up; *P*\<0.01) showed a significant association with undertreatment. To describe the effect of these three variables better, we assembled a new composite variable comprising all the possible mutually exclusive combinations of the original predictors transposed to 12 possible levels where we estimated the prevalence of undertreatment. Estimates ranged from 9.8 (patients already admitted to hospice, receiving adjuvant therapy) to 55.3% (new cases admitted to pain or palliative care centre, not receiving adjuvant treatment). [Figure 3](#fig3){ref-type="fig"} confirms that each of the three variables actually has an effect on the occurrence of undertreatment, and within each type of recruiting centre, the other two variables may stratify patients with different frequency. Nevertheless, patients in a hospice had a lower prevalence (range=9.8--30.4%) than those in oncology centres (16.3--39.3%) and pain and palliative centres (11.8--55.3%).

[Table 6](#tbl6){ref-type="table"} shows the prevalence of patients receiving the treatment that we considered appropriate for each specific condition, and the associations with type of patient and type of centre. Non-compliance with the treatments identified was generally high, with some variability according to the type of patient and the recruiting centre. New cases had higher non-compliance rates in general. In patients with neuropathic pain, non-compliance was higher in oncology centres; in patients with severe worst pain, non-compliance rates were higher in palliative and pain centres.

Discussion
==========

Advances in diagnosis and therapy have extended the life expectancy of cancer patients, but for most of them, the last part of their life is impaired by pain, depression and other symptoms related to the disease and treatments that become major contributors to suffering. Considerable evidence from clinical experience shows that cancer pain may be controlled in up to 90% cases with available therapies ([Ventafridda *et al*, 1987](#bib30){ref-type="other"}; [Grond *et al*, 1996](#bib17){ref-type="other"}; [Mercadante, 1999](#bib22){ref-type="other"}). The epidemiology of cancer pain and related treatments in Italy is not well documented, but undertreatment is to be expected as strong opioids are prescribed only to a small proportion of eligible patients. ([De Conno *et al*, 2005](#bib11){ref-type="other"}; [Osservatorio Nazionale sull\'impiego dei farmaci, 2007](#bib25){ref-type="other"}). This study reporting the results of an observational study produced a significant picture of the management of cancer pain for an unselected population of cancer patients in the care of different Italian specialist facilities (oncology clinics, pain and palliative care and hospice centres). Forthcoming studies will describe the longitudinal change over time of both therapeutic and outcome variables and will compare the effectiveness of different analgesic strategies ([Apolone *et al*, 2006b](#bib2){ref-type="other"}).

The main aim of this analysis was to estimate the quality of analgesic drug regimens across different settings. We applied the PMI as recommended by [Cleeland *et al* (1994)](#bib8){ref-type="other"} using the worst intensity of pain to calculate the score. By changing the pain measure criteria, it yields figures which cannot be fully compared, as suggested by earlier research ([de Wit *et al*, 1999](#bib12){ref-type="other"}).

The prevalence of undertreatment found in this study (25% in the whole sample and up to 55% in some groups) compares the earlier results ranging from as low as 7--9% in a survey in the United Kingdom ([Russell *et al*, 2006](#bib27){ref-type="other"}) to 82% in a sample of non-small cell lung cancer patients entering clinical trials in Italy ([Di Maio *et al*, 2004](#bib14){ref-type="other"}), with the weighted overall mean of 43% across 26 different studies ([Deandrea *et al*, 2008](#bib13){ref-type="other"}).

When the factors associated with negative PMI were examined in this study, undertreatment tended to be lower according to the year of publication, showing a time trend between articles published before and after 2000; it was also associated with socioeconomic and geographic factors: patients coming from Asian countries and patients with lower socioeconomical status had the highest risk of undertreatment. Other factors that predict a negative PMI consistently were having a less advanced disease and the discrepancy between the patient\'s and physician\'s assessments of pain intensity ([Russell *et al*, 2006](#bib27){ref-type="other"}; [Deandrea *et al*, 2008](#bib13){ref-type="other"}).

This study shows that the baseline PMI scores are also influenced by the time of referral. Patients just referred to a centre had negative PMI more often (41%) than patients already followed by the centre. This factor has been underestimated in the literature and it should, therefore, be stressed that the patient\'s pain history is a significant variable in evaluating epidemiological and therapy-related information. A selection bias can also have occurred in our study as physicians may have referred those patients who needed expert advice for treating their pain, although 20% of negative PMI persisted also in patients referred to the centre since a long time ([Table 3](#tbl3){ref-type="table"}).

In this study, the setting of care and receiving an adjuvant analgesic drug treatment were also predictors of the PMI status. Being admitted to a hospice and the use of an adjuvant drug were in fact independently associated with more adequate analgesic treatments. These observations might be interpreted as indicative of a delay of starting strong opioids influenced by attitudes of practice and setting of care. Time of patient referral to the centre, considered as very important, is not enough to explain pain and pain treatment history. Organisation and expertise in pain management and monitoring by different specialists and in different settings, such as an in-patient hospice or outpatient pain clinic, probably influence the recourse to more potent drugs.

The use of adjuvants for neuropathic pain is an indicator of compliance with available guidelines ([SIGN, 2008](#bib28){ref-type="other"}), and perhaps its association with more appropriate opioid use is consistent in explaining individual differences among operators even in apparently similar settings.

Although the usefulness of the PMI is proved by the large number of studies that have used this score since 1994, some drawbacks are well known ([Deandrea *et al*, 2008](#bib13){ref-type="other"}) and others may be derived from our analysis. It takes into account only one characteristic of pain (the intensity) and the most potent opioid prescribed, but does not reflect other pain characteristics, opioid titration, route of administration, patient\'s compliance, rescue and adjuvant therapies, or the use of non-pharmacological therapies. For instance, for patients with neuropathic pain and severe pain, it might be more appropriate to add an adjuvant drug for neurophatic pain rather than changing the type of analgesic drugs or increase its dosage. Eventually, PMI is a static measure that allows cross-sectional evaluation, but cannot adequately assess events over time. Given the longitudinal nature of the study, we were also able to prospectively evaluate the PMI negative status at 4 weeks. As expected, as it is very sensitive to the administration of opioids, the proportion of undertreatment falls substantially approaching 5%, with little variability across variables (type of centre and patient). As a conclusion, PMI can be viewed as a preliminary indicator (a screener) of potential undertreatment that requires a further more specific evaluation.

When we used a selected list of indicators to describe the attitude of Italian physicians towards treating subgroups of patients with specific clinical conditions, we found that the general picture captured by PMI does reflect substantial undertreatment. These indicators also added important information about less than optimal practices. Only 59% of patients with severe worst pain actually received a strong opioid as 'around the clock therapy\' at the time of study enrolment, 44% with neuropathic pain had an adjuvant drug prescribed and 24% with breakthrough pain had a 'rescue\' analgesic. The interpretation of the fact that only 38% of patients with bone metastasis actually were receiving bisphosphonates is less straightforward as the role of these drugs to obtain immediate pain relief remains uncertain, despite results from a *Cochrane Review* document that the addition of bisphosphonates can be beneficial ([Wong and Wiffen, 2002](#bib32){ref-type="other"}). Interestingly, also these indicators were associated with the place of care.

In summary, in this prospective observational study, the PMI method indicated a high prevalence of analgesic undertreatment in Italy, around 50% in some subgroups, which varies according to several factors related to the characteristics of the cases and to some structural and organisation variables. These findings confirm the results of a systematic review ([Deandrea *et al*, 2008](#bib13){ref-type="other"}). Other clinical indicators suggest that undertreatment is substantial in some specific subgroups, with underuse of specific adjuvant drugs. Recourse to the WHO third-level drugs is still delayed in a large percentage of patients with cancer pain, half of whom are still treated with anticancer drugs, but very few (31%) had adequate information about prognosis.

It is likely that after the first impact of the WHO guidelines on cancer pain after their first publication in 1986, the present overall strategy for managing cancer pain in Italy would need more structured interventions to improve and standardise quality of care. Evidences about the most effective interventions in changing the outcome of current practice in cancer pain management are scarce. Although guidelines implementation proved to have an impact on patient-reported outcomes ([Ventafridda *et al*, 1990](#bib31){ref-type="other"}; [Du Pen *et al*, 1999](#bib15){ref-type="other"}), educational and quality improvement programmes had no effect in modifying patients\' pain severity, but a beneficial effect was seen as the result of providing specialised palliative care ([Goldberg and Morrison, 2007](#bib16){ref-type="other"}). Others have advocated the efficacy of the implementation of institutional policies, adoption of clinical pathways and pain consultation models ([Brink-Huis *et al*, 2008](#bib5){ref-type="other"}). In Italy where lack of homogeneous service development for patients with cancer pain, cultural barriers and poor guidelines dissemination are likely to exist, a combination of approaches adopted by professional and scientific associations, regulatory authorities and institutions could improve the way in which the pain is managed in this patient population.

Our results also support the idea that palliative care, like the prevention and relief of symptoms in cancer patients, needs to be a component of patient care also during anticancer treatment, and not merely at the end of life. A wider approach is therefore needed, with better education on palliative care and pain management to improve the use of opioids, to standardise the practice of managing cancer pain to minimum standards ([Maltoni, 2008](#bib23){ref-type="other"}; [Meyers *et al*, 2004](#bib24){ref-type="other"}) and to improve the physician--patient communication ([Harrington and Smith, 2008](#bib19){ref-type="other"}).
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###### 

Characteristics of patients at baseline (*n*=1801)

  **Characteristics**                                   **%**   **Mean, s.d.**
  ----------------------------------------------------- ------- ----------------
  Age                                                           63.9, 12.1
  Female                                                47.3     
  Karnofsky PS, \<50                                    11.5     
                                                                 
  *Primary tumour*                                               
   Lung                                                 21.8     
   Breast                                               15.9     
   Colorectal                                           13.7     
   Prostate                                             7.9      
   Gynecological                                        6.1      
   Pancreas                                             6.0      
   Genitourinary                                        6.1      
   Stomach                                              5.5      
   Head and neck                                        4.5      
   Liver                                                1.2      
   Others                                               9.9      
   Unknown                                              1.4      
                                                                 
  Bone metastasis                                       46.8     
                                                                 
  Earlier surgery                                       58.0     
  Earlier chemotherapy                                  65.2     
  Earlier hormonotherapy                                20.0     
  Earlier radiotherapy                                  40.3     
  Others                                                5.4      
                                                                 
  Ongoing chemotherapy                                  49.0     
                                                                 
  Patients aware of prognosis (reported by physician)   30.3     
                                                                 
  *Type of recruiting centre*                                    
   Oncology centre                                      59.4     
   Palliative care                                      17.0     
   Pain centre                                          15.1     
   Hospice                                              7.7      
   Others                                               0.8      
                                                                 
  *Time of recruiting*                                           
   New cases                                            25.7     
   Already admitted                                     74.3     
                                                                 
  *Pain intensity (0--10)*                                       
   Worst (previous week)                                        6.8, 2.2
   Mean (previous week)                                         4.5, 2.0
   Current                                                      3.4, 2.7
   Least (previous week)                                        2.6, 2.0
                                                                 
  *Pain intensity (according to WHO)*                           
   None                                                 1.1      
   Mild                                                 26.0     
   Moderate                                             65.9     
   Severe                                               7.1      
                                                                 
  Pain relief (0--100)                                          55.1, 26.4
                                                                 
  Patients with breakthrough pain                       48.4     
  Patients with neuropathic pain                        25.7     
                                                                 
  *Type of analgesic care*                                       
   Around the clock therapy                                      
    None                                                5.9      
    Only NSAID                                          8.8      
    Only weak opioids                                   10.6     
    NSAID with weak opioids                             14.1     
    One strong opioid                                   38.3     
    NSAID/weak opioid+strong opioid                     19.2     
    More than one strong opioid                         3.1      
                                                                 
   Rescue therapy                                                
    None                                                53.2     
    Only NSAID                                          24.9     
    Only weak opioids                                   3.8      
    NSAID with weak opioids                             2.9      
    One strong opioid                                   11.8     
    NSAID/weak opioid+strong opioid                     3.2      
    More than one strong opioid                         0.2      
                                                                 
   Adjuvant therapy                                              
    Corticosteroids                                     40.1     
    Anticonvulsants                                     15.8     
    Antidepressants                                     10.8     
    Bisphosphonates                                     18.5     

###### 

Percentages of patients with negative PMI score for different pain items (from Brief Pain Inventory)

                                     **Time of recruiting**   
  --------------------------- ------ ------------------------ ------
  Worst pain                  25.3   20.4                     38.3
  Least pain                  8.9    6.0                      16.7
  Current pain                12.2   8.5                      22.0
  Mean pain                   14.6   11.3                     23.7
  Overall pain (four items)   14.0   11.1                     21.8

###### 

Percentages of patients with negative PMI scores according to the type of recruitment (new patients or patients already admitted at the time of inclusion in the study)

                                 **Days since admission to the centre**                 
  ------------------------------ ---------------------------------------- ------ ------ ------
  *N*                            282                                      171    210    1101
                                                                                         
  *PMI negative scores*                                                                  
   *n*                           126                                      48     46     222
   %                             44.7                                     28.1   21.9   20.2
                                                                                         
  Cochran--Armitage trend test   *χ*^2^=8.124                                            
                                 *P*\<0.0001                                             
                                                                                         
  Heterogeneity test             Statistic=73.8092                                       
                                 *P*\<0.0001                                             

###### 

Percentages of patients with negative PMI scores according to selected variables

                                 ***N***   **%**   **OR**   **95% CI**   ***P*-value**
  ------------------------------ --------- ------- -------- ------------ ---------------
  *Age (years)*                                                           
   \<51                          254       22.8    1.00     ---          ---
   51--60                        402       25.4    1.15     0.79--1.66   0.4610
   61--70                        558       23.5    1.04     0.73--1.47   0.8415
   \>70                          583       28.0    1.31     0.93--1.85   0.1227
                                                                          
  *Sex*                                                                   
   Male                          947       24.2    1.00     ---          ---
   Female                        850       26.5    1.13     0.91--1.40   0.2650
                                                                          
  *Bone metastasis*                                                      
   Yes                           842       22.3    1.00     ---          ---
   No                            955       27.9    1.34     1.08--1.67   0.0072
                                                                          
  *Ongoing chemotherapy*                                                 
   Yes                           883       23.0    1.00     ---          ---
   No                            914       27.5    1.27     1.02--1.57   0.0294
                                                                          
  *Type of recruiting centre*                                            
   Oncology centre               1066      23.7    1.48     0.93--2.35   0.0978
   Pain center                   271       34.0    2.44     1.47--4.05   0.0006
   Palliative care               307       26.1    1.67     1.01--2.78   0.0471
   Hospice                       138       17.4    1.00     ---          ---
   Others                        15        33.3    2.38     0.74--7.58   0.1440
                                                                          
  *Type of cancer*^a^                                                    
   NSCLC                         391       22.5    1.15     0.67--1.98   0.6214
   Breast                        287       23.7    1.23     0.70--2.15   0.4757
   Colorectal                    247       31.2    1.79     1.02--3.13   0.0416
   Prostate                      142       21.1    1.06     0.56--2.00   0.8617
   Pancreas                      108       24.1    1.25     0.65--2.42   0.5037
   Stomach                       99        20.2    1.00     ---          ---
                                                                          
  *Breakthrough pain*                                                    
   Yes                           870       24.2    1.00     ---          ---
   No                            927       26.4    1.14     0.92--1.41   0.2409
                                                                          
  *Neuropathic pain*                                                     
   Yes                           455       24.8    1.00     ---          ---
   No                            1314      25.2    1.02     0.80--1.30   0.8806
                                                                          
  *Analgesic adjuvant therapy*                                           
   Yes                           1078      18.1    1.00     ---          ---
   No                            719       36.0    2.55     2.05--3.17   \<0.0001

Only cancers with frequency \>5%.

###### 

Multivariate association (multivariable logistic regression) between selected variables and PMI negative scores

                                 **OR**   **95% CI**    ***P*-value**
  ------------------------------ -------- ------------- ---------------
  *Age (years)*                                          
   \<51                          1.00     0.69--1.46    0.9916
   51--60                        1.04     0.75--1.44    0.8021
   61--70                        1.00     ---           ---
   \>70                          1.21     0.91--1.62    0.1870
                                                         
  *Sex*                                                  
   Male                          1.00     ---           ---
   Female                        1.21     0.96--1.53    0.1082
                                                         
  *Bone metastasis*                                      
   Yes                           1.00     ---           ---
   No                            1.05     0.82---1.35   0.6795
                                                         
  *Ongoing chemotherapy*                                
   Yes                           1.00     ---           ---
   No                            1.17     0.91--1.51    0.2195
                                                         
  *Type of recruiting centre*                           
   Palliative care+pain centre   2.09     1.27--3.45    0.0038
   Oncology centre               2.09     1.26--3.45    0.0041
   Hospice                       1.00     ---           ---
                                                         
  *Type of cancer*                                       
   Pancreas                      1.00     ---           ---
   Colorectal                    1.43     0.82--2.48    0.2047
   Gynecologic                   1.42     0.80--2.51    0.2282
   Others                        1.15     0.69--1.91    0.5865
                                                         
  *Breakthrough pain*                                    
   Yes                           1.00     ---           ---
   No                            1.09     0.86--1.37    0.4793
                                                         
  *Neuropathic pain*                                     
   Yes                           1.14     0.87--1.49    0.3514
   No                            1.00     ---           ---
                                                         
  *Analgesic adjuvant therapy*                          
   Yes                           1.00     ---           ---
   No                            2.40     1.89--3.04    \<0.0001
                                                         
  *Time of recruiting*                                   
   Already admitted              1.00     ---           ---
   New cases                     2.46     1.88--3.20    \<0.0001

###### 

Compliance with selected indications according to specific subgroups

                                           **Type of patient**   **Type of centre**                                                          
  --------------------------------- ------ --------------------- -------------------- ------- ---------- ------ ------ ------ ------ ------- ----------
  *Breakthrough pain*                                                                                                                        
   Rescue (no)                                                                                                                               
    *n*                             663    174                   474                  5.13    0.0236     367    138    105    53     1.87    0.6008
    %                               76.2   82.1                  73.9                                    75.5   79.8   76.1   72.6            
                                                                                                                                              
   Rescue (yes)                                                                                                                              
    *n*                             207    38                    167                                     119    35     33     20              
    %                               23.8   17.9                  26.1                                    24.5   20.2   23.9   27.4            
                                                                                                                                              
   Total                            870    212                   641                                     486    173    138    73              
                                                                                                                                              
  *Neuropathic pain*                                                                                                                         
   Adjuvant (no)                                                                                                                              
    *n*                             252    65                    180                  3.68    0.0547     154    34     51     13     11.37   0.0099
    %                               55.4   63.1                  52.3                                    61.8   42.5   53.1   43.3            
                                                                                                                                              
   Adjuvant (yes)                                                                                                                            
    *n*                             203    38                    164                                     95     46     45     17              
    %                               44.6   36.9                  47.7                                    38.2   57.5   46.9   56.7            
                                                                                                                                              
   Total                            455    103                   344                                     249    80     96     30              
                                                                                                                                              
  *Bone metastasis*                                                                                                                          
    Bisphosphonates (no)                                                                                                                     
    *n*                             522    159                   354                  34.91   \<0.0001   252    108    93     69     50.55   \<0.0001
    %                               62.0   80.3                  56.1                                    52.0   75.5   69.4   86.3            
   Bisphosphonates (yes)                                                                                                                     
    *n*                             320    39                    277                                     233    35     41     11              
    %                               38.0   19.7                  43.9                                    48.0   24.5   30.6   13.8            
                                                                                                                                              
   Total                            842    198                   631                                     485    143    134    80              
                                                                                                                                              
                                                                                                                                              
  *Worst pain* \>*7*                                                                                                                         
   Around the clock therapy (no)                                                                                                             
    *n*                             327    140                   178                  25.91   \<0.0001   174    64     75     14     12.61   0.0056
    %                               40.9   53.2                  34.2                                    38.7   43.2   51.0   25.5            
                                                                                                                                              
   Around the clock therapy (yes)                                                                                                            
    *n*                             473    123                   343                                     276    84     72     41              
    %                               59.1   46.8                  65.8                                    61.3   56.8   49.0   74.5            
                                                                                                                                              
   Total                            800    263                   521                                     450    148    147    55              

Logistic regression test.

[^1]: See Appendix
